PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global Summit for Oncology Innovators. This abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results